FY2025 EPS Estimates for Hologic Reduced by Zacks Research

Hologic, Inc. (NASDAQ:HOLX) – Analysts at Zacks Research lowered their FY2025 earnings estimates for shares of Hologic in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $4.25 per share for the year, down from their previous forecast of $4.26. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.14 EPS and FY2026 earnings at $4.59 EPS.

A number of other brokerages also recently issued reports on HOLX. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target for the company. in a report on Monday, February 3rd. Jefferies Financial Group began coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target for the company. Leerink Partners downgraded shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Wolfe Research initiated coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Finally, Raymond James reaffirmed an “outperform” rating and set a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $84.62.

Hologic Stock Down 0.7 %

HOLX stock opened at $61.01 on Friday. The firm has a 50-day moving average of $66.26 and a two-hundred day moving average of $74.19. The company has a market cap of $13.69 billion, a price-to-earnings ratio of 19.25, a PEG ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic has a 12 month low of $60.34 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%.

Hedge Funds Weigh In On Hologic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Swedbank AB raised its stake in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares in the last quarter. GSA Capital Partners LLP raised its stake in Hologic by 22.2% during the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock worth $469,000 after acquiring an additional 1,048 shares in the last quarter. OneDigital Investment Advisors LLC raised its stake in Hologic by 5.4% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock worth $576,000 after acquiring an additional 360 shares in the last quarter. Empowered Funds LLC raised its stake in Hologic by 8.8% during the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock worth $294,000 after acquiring an additional 291 shares in the last quarter. Finally, Pathstone Holdings LLC raised its stake in Hologic by 7.7% during the 3rd quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider’s stock worth $2,422,000 after acquiring an additional 2,121 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.